Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innate Pharma SA ( (FR:IPH) ) has issued an announcement.
On January 21, 2025, Innate Pharma announced an upcoming investor and analyst event in New York to showcase IPH4502, its lead Nectin-4 Antibody Drug Conjugate program, which targets several types of solid tumors. The event, scheduled for February 5, 2025, reflects Innate Pharma’s strategic focus on ADC programs and aims to highlight the potential advancements in cancer treatment that IPH4502 offers, following the FDA’s clearance for its Phase 1 clinical study in September 2024.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company specializing in the development of immunotherapies for cancer patients. The company focuses on harnessing the innate immune system through its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -40.34%
Average Trading Volume: 616
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $150M
See more data about IPH stock on TipRanks’ Stock Analysis page.
